Benefits
CD38 Inhibition / NAD+ Preservation (Theoretical)
CD38 is an enzyme that breaks down NAD+. In a 2013 laboratory study, apigenin blocked CD38 in cells and raised NAD+ in the tissues of obese mice, which also showed better metabolic measurements. That is a mechanism finding in cells and animals. No human study has shown that taking apigenin raises NAD+ or affects aging in any way, and the concentrations that inhibit CD38 in the lab are far higher than the blood levels an oral supplement typically produces.
Anxiolytic / Calming Effects
In a 1995 laboratory and animal study, apigenin competed with the benzodiazepine drug flunitrazepam for binding at the GABA-A receptor and reduced anxiety-like behavior in mice on maze tests. Higher doses also cut the animals' movement by about 26 percent. This is the usual explanation for why chamomile feels calming. No human trial of apigenin for stress or anxiety is cited on this page, so a calming effect in people is unproven.
Sleep Support
Chamomile has a long traditional use as a bedtime tea, and a 2024 review discusses apigenin's GABA-A receptor activity as a possible reason for it. That review summarizes mostly cell and animal work. No human trial of apigenin itself for sleep is cited on this page, so any effect on how quickly you fall asleep or how well you sleep is unproven.
Anti-Inflammatory / Antioxidant
Inhibits NF-κB, COX-2 and iNOS in test tube studies, and it scavenges free radicals in laboratory assays. These are cell-based findings only. No study cited here measured inflammation, antioxidant status or any heart-related outcome in people taking apigenin.
Cancer Research (Laboratory and Animal Only)
Apigenin causes cancer cells to die in test tube experiments (breast, prostate, colon and lung cell lines) and slows tumor growth in some animal models. None of this has been tested in people, and no reference on this page is a human cancer study. Apigenin is not a treatment or a preventive for cancer and should never replace medical care.
Mechanism of action
CD38 Inhibition (NAD+ Pathway)
CD38 is the major NAD+-degrading enzyme; CD38 expression increases with age, contributing to NAD+ decline. Apigenin inhibits CD38 in vitro and animal studies — theoretical NAD+ preservation. Mechanism makes apigenin popular in NMN/NR/longevity stacks. Note: in vitro CD38 IC50 is in micromolar range; achievable plasma levels with oral supplementation are typically nanomolar — clinical CD38 inhibition uncertain.
GABA-A Benzodiazepine Receptor Modulation
Apigenin is a ligand at the benzodiazepine site of the GABA-A receptor — mild positive allosteric modulator. It is far weaker at that site than prescription benzodiazepines. The calming effect was measured in mice, not in humans, and it is the usual explanation offered for chamomile's traditional calming reputation.
Aromatase Inhibition
Apigenin modestly inhibits aromatase enzyme (CYP19) — the enzyme that converts androgens to estrogens. What this means for people is unknown, because it has only been seen in laboratory tests and no cited study measured hormone levels in humans after taking apigenin. If you have a hormone-sensitive condition, ask your doctor before using a concentrated supplement.
NF-κB and Inflammatory Pathway Inhibition
Modulates NF-κB signaling, reduces COX-2 and iNOS expression in cell studies. Whether this changes inflammation in the human body has never been tested.
Clinical trials
Laboratory and animal study published in Planta Medica in 1995, testing whether apigenin binds the brain's benzodiazepine receptor and whether it changes anxiety-like behavior in mice on the elevated plus maze and hole board tests.
Mice. No people were studied.
Apigenin competed with the benzodiazepine drug flunitrazepam for receptor binding (Ki about 4 micromolar) and reduced anxiety-like behavior in the mice. Higher doses cut the animals' movement by about 26 percent, which looks like sedation rather than calm. Because this was done in mice, it does not show that apigenin reduces anxiety in people.
Multiple preclinical studies of apigenin's CD38 inhibition and NAD+ preservation effects in cell culture and animal models.
Cell culture and rodent models.
Apigenin blocked CD38 in cell experiments and raised NAD+ in the tissues of obese mice, and those mice showed better metabolic measurements. No human trial of apigenin for CD38 or NAD+ is cited on this page. Its popularity in longevity stacks comes from this cell and animal work, not from results in people.